Drugs / MOL4239
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04702503 | Mar → Nov 2019 | mycosis fungoides | Moleculin Biotech, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01826201 | Mar → Aug 2013 | psoriasis | Moleculin, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2020-02-18 | WPD Pharmaceuticals Sp. z o.o. | Results WPD Pharmaceuticals’ Wp1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials wpdpharmaceuticals.com ↗
The final results supported the safety of topical WP1220 and demonstrated a median improvement in the Composite Assessment of Index Lesion Severity (CAILS) score of 56% in treated (index) lesions for patients completing the study. |
| 2020-02-18 | Moleculin Biotech, Inc. | Results Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions moleculin.com ↗
The final results supported the safety of topical WP1220 and demonstrated a median improvement in the Composite Assessment of Index Lesion Severity (CAILS) score of 56% in treated (index) lesions for patients completing the study. |
| 2019-11-19 | Moleculin Biotech, Inc. | Results Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients moleculin.com ↗ |
| 2019-02-07 | Moleculin Biotech, Inc. | Regulatory Moleculin Announces Approval for Third Drug to Commence Clinical Trials moleculin.com ↗
today announced it has received approval to begin clinical trials in Poland for its STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (“CTCL”). |
| 2018-08-09 | Moleculin Biotech, Inc. | Regulatory Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial moleculin.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-18 | WPD Pharmaceuticals Sp. z o.o. | WPD Pharmaceuticals’ Wp1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials wpdpharmaceuticals.com ↗ |
| 2020-02-18 | Moleculin Biotech, Inc. | Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions moleculin.com ↗ |
| 2019-11-19 | Moleculin Biotech, Inc. | Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients moleculin.com ↗ |
| 2019-02-07 | Moleculin Biotech, Inc. | Moleculin Announces Approval for Third Drug to Commence Clinical Trials moleculin.com ↗ |
| 2018-08-09 | Moleculin Biotech, Inc. | Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial moleculin.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOL4239 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01826201 ↗ |
| Known as | WP1220 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04702503 ↗ |
| Action | Inhibit | “Inhibitor of STAT3 Activation” NCT04702503 ↗ |
| Modality | Small molecule | — CHEMBL4594434 ↗ |
| Route | Topical | “apply 10% MOL4239 ointment to one target lesion” NCT01826201 ↗ |
| Target | STAT3 | “Inhibitor of STAT3 Activation” NCT04702503 ↗ |